PTD-DBM vs Matrixyl.

PTD-DBM is a synthetic, cell-permeable peptide whose name stands for "Protein Transduction Domain–Dishevelled Binding Motif." It fuses a short protein-transduction (cell-penetrating) domain to a peptide sequence that mimics the Dishevelled-binding region of the protein CXXC5, allowing it to act as a competitive decoy. It was created as a research tool to manipulate Wnt/β-catenin signaling in skin and hair-follicle biology and is not a drug, nutritional product, or approved therapeutic.

Matrixyl is the trade name (Sederma/Croda) for palmitoyl pentapeptide-4, also written pal-KTTKS or palmitoyl-Lys-Thr-Thr-Lys-Ser. It is a synthetic cosmetic peptide consisting of a five-amino-acid fragment of type I procollagen (the KTTKS sequence) conjugated to palmitic acid, a fatty-acid tail added to improve lipophilicity and skin penetration. It is sold as a topical anti-aging skincare active, not as a drug or an injectable; the related blend "Matrixyl 3000" pairs a different peptide (palmitoyl tripeptide-1 / pal-GHK) with palmitoyl tetrapeptide-7.

CXXC-type zinc finger protein 5 (CXXC5) is a negative-feedback regulator of canonical Wnt/β-catenin signaling that works by binding the scaffolding protein Dishevelled (Dvl), preventing Dvl from transmitting the Wnt signal. PTD-DBM carries a sequence that imitates the Dvl-binding motif, so it competitively occupies that interface and disrupts the CXXC5–Dvl interaction. Freed from CXXC5 inhibition, Dvl can stabilize β-catenin, which in turn drives transcriptional programs associated with the anagen (growth) phase of the hair cycle, dermal-papilla activity, and epithelial proliferation in wounds. In the founding work this de-repression of Wnt signaling was the proposed basis for both accelerated hair regrowth and wound-induced hair neogenesis (de novo follicle formation within healing skin).

KTTKS is a sub-fragment of the C-terminal propeptide of type I collagen. Liberation of such procollagen fragments during matrix turnover is thought to act as a feedback signal that up-regulates new extracellular matrix synthesis, so the peptide is described as a "matrikine" or signal peptide rather than a hormone or growth factor. In cultured human dermal fibroblasts, KTTKS and pal-KTTKS have been reported to stimulate production of type I and III collagen, fibronectin, and glycosaminoglycans. The palmitoyl tail is non-functional pharmacologically; its role is to make the otherwise hydrophilic peptide lipophilic enough to cross the stratum corneum. The peptide does not relax muscle (it is not a "Botox-like" neuromodulator, unlike acetyl hexapeptide-8/Argireline).

The evidence base is preclinical. The foundational study (Lee et al., J Invest Dermatol 2017, PMID 28595998) reported that CXXC5 is elevated in balding human scalp and that disrupting the CXXC5–Dishevelled interaction with the competing peptide activated Wnt/β-catenin signaling, accelerated hair regrowth, and promoted wound-induced hair neogenesis in mice; effects were enhanced when combined with valproic acid (a GSK3β-modulating Wnt activator), and Cxxc5-knockout mice phenocopied the benefit. Earlier work established CXXC5 itself as a negative regulator of cutaneous wound healing (Lee et al., J Exp Med 2015, PMID 26056233), and a 2023 study (Cells, PMID 36831222) linked CXXC5 to DHT/PGD2-driven androgenetic alopecia, supporting the target's relevance. The same Yonsei group later advanced a small-molecule Wnt activator, KY19382 (Br J Pharmacol 2021, PMID 33751552), as a more drug-like successor. Critically, no human clinical trials of PTD-DBM have been published; human relevance rests on cultured human follicle cells and on the observation of elevated CXXC5 in bald scalp, not on controlled efficacy data in people.

Human evidence comes from cosmetic split-face/vehicle-controlled topical trials, not drug-grade efficacy programs. The most cited is Robinson et al. (Int J Cosmet Sci, 2005), a 12-week double-blind, vehicle-controlled, split-face study in 93 women (ages 35-55) where a moisturizer with 3 ppm pal-KTTKS gave statistically significant reductions in fine lines/wrinkles versus the same vehicle by quantitative image analysis, expert grading, and self-assessment, and was well tolerated. A daily-moisturizer study published in JAAD (2004) similarly reported improvement in the appearance of aging skin. A 2023 double-blind RCT in the Journal of Clinical and Aesthetic Dermatology compared palmitoyl pentapeptide-4 cream with acetyl hexapeptide-3 for crow's feet. Importantly, headline figures often quoted in marketing (e.g. "stimulates collagen by ~350%" or large fibronectin increases) derive from in-vitro fibroblast assays, not human skin, and effect sizes in human trials are modest; independent head-to-head data versus retinoids remain limited.

There are no published human safety data, pharmacokinetics, or toxicology studies for PTD-DBM; it has been used only as an experimental reagent in animal and cell-culture models, so its safety profile in humans is genuinely unknown. As a cell-penetrating peptide that broadly de-represses Wnt/β-catenin signaling, a theoretical concern is that sustained or systemic Wnt activation could have off-target effects on tissues where the pathway influences proliferation, though no such outcomes have been characterized for this peptide specifically. Material sold online is research-use-only, is not produced or tested to pharmaceutical quality standards, and purity, sterility, and identity cannot be assumed. Anyone encountering PTD-DBM should treat it strictly as an unapproved experimental compound.

In the published topical trials pal-KTTKS was well tolerated, with low rates of irritation, erythema, or sensitization and a generally favorable cosmetic safety profile, one reason it is often positioned as a gentler alternative to retinoids. The Cosmetic Ingredient Review and EU cosmetic frameworks treat palmitoyl oligopeptides as safe for topical use at the low concentrations used in finished products. That said, safety data are specific to topical, leave-on cosmetic use at trace concentrations; there is no established safety profile for injected, oral, or high-concentration use, and such routes are not a recognized use of this ingredient. As with any topical, individual allergic or irritant contact reactions are possible, and pregnancy/long-term systemic data are essentially absent because systemic exposure from topical use is expected to be negligible.

PTD-DBM is an investigational research compound; it is not approved by the FDA or any major regulator for any indication, and it is not in marketed dermatologic products. It is not a WADA-listed substance, and the published work remains preclinical with no registered human clinical program for the peptide itself.

Matrixyl/palmitoyl pentapeptide-4 is regulated as a cosmetic ingredient, not an FDA-approved drug; it makes appearance ("cosmetic") claims rather than treatment claims and has not undergone FDA drug approval. It is widely used in over-the-counter skincare in the US, EU, and elsewhere, and is not a controlled substance or a WADA-prohibited compound.